SecProbe.io

December 16, 2011
 Via E-mail

Peter G. Traber, M.D. Chief Executive Officer and President Galectin Therapeutics Inc. 7 Wells Avenue Newton, MA  02459
Re: Pro-Pharmaceuticals, Inc., now kn own as Galectin Therapeutics Inc.
  Form 10-K for the Fiscal Year Ended December 31, 2010
Filed March 15, 2011
  File No. 001-31791

Dear Dr. Traber:
 We have reviewed your filing and have the following comment.
 Please respond to this letter within ten business days by amending your filing, by
providing the requested information, or by advi sing us when you will provide the requested
response.  If you do not believe our comment applies to your fact s and circumstances or do not
believe an amendment is appropriate, pl ease tell us why in your response.
 After reviewing any amendment to your filing and the information you provide in
response to our comment, we may have additional comments.

Signatures

1. We note you have not identified the principal executive officer, princi pal financial officer
and principal accounting officer or controller of the registrant among the signatories.  If
Messrs. Zucconi and Squeglia signed the filing in these capacities, respectively, please so
advise us and confirm that all required signatories will properly execute future filings on Form 10-K and that you will identify which persons have signed in the required capacities, i.e., principal executive officer , principal financial officer, principal
accounting officer or controller  and director.  Alternativ ely, if Messrs. Zucconi and
Squeglia were not acting in such capacities , please amend your Form 10-K to have your
principal executive officer, prin cipal financial officer and pr incipal accounting officer or
controller sign your Form 10-K.   See Inst ruction D.2(a) of Form 10-K for further
information.  We urge all persons who are responsible for th e accuracy and adequacy of the disclosure
in the filing to be certain that the filing incl udes the information the Securities Act of 1933 and
all applicable Securities Act rules require.  Since the company and its management are in

Peter G. Traber Galectin Therapeutics Inc. December 16, 2011 Page 2

 possession of all facts relating to a company’s disc losure, they are responsible for the accuracy
and adequacy of the disclosures they have made.
Notwithstanding our comments, in the event you request acceleration of  the effective date
of the pending registration statement please pr ovide a written statement from the company
acknowledging that:

 should the Commission or the staff, acting purs uant to delegated authority, declare the
filing effective, it does not foreclose the Co mmission from taking any action with respect
to the filing;

 the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the company from its full responsibility for
the adequacy and accuracy of the disclosure in the filing; and

 the company may not assert staff comments a nd the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.  Please contact Karen Ubell, Staff Attorne y, at (202) 551-3873, Jennifer Riegel, Special
Counsel, at (202) 551-3575 or me at  (202) 551-3715 with any questions.

Sincerely,

 /s/ Jennifer Riegel for

Jeffrey Riedler Assistant Director